VERA
HealthcareVera Therapeutics, Inc.
$47.07
$-1.55 (-3.19%)
Jan 5, 2026
Price History (1Y)
Analysis
Vera Therapeutics, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $3.34 billion and 224 employees. The company's industry classification is biotechnology. Financially, Vera Therapeutics has reported net income of $-251,943,008 and an EBITDA of $-269,792,992 for its trailing twelve months. Its gross margin, operating margin, and profit margin are all at 0.0%. The company's returns on equity and assets are -73.2% and -38.1%, respectively. Vera Therapeutics has a debt-to-equity ratio of 19.36 and a cash balance of $497.39 million against a debt of $77.22 million. The company's valuation metrics include a forward P/E ratio of -10.41, an EV/EBITDA ratio of -9.96, and a price-to-book ratio of 7.54. The 52-week high and low prices for Vera Therapeutics' stock are $56.05 and $18.53, respectively, with a beta of 1.16.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Visit website →Key Statistics
- Market Cap
- $3.34B
- P/E Ratio
- N/A
- 52-Week High
- $56.05
- 52-Week Low
- $18.53
- Avg Volume
- 1.54M
- Beta
- 1.16
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 224